Explore 130+ historical metrics & ratios
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Prestige Consumer Healthcare is a diversified over-the-counter healthcare products company with a portfolio of established brands across gastrointestinal (Dramamine, Monistat), eye/ear care (Clear Eyes, Debrox), women's health (Summer's Eve, Monistat), and dermatology (Compound W) categories. The company operates a capital-light model focused on acquiring mature brands with strong consumer recognition, optimizing marketing spend, and generating consistent cash flow. With 55.8% gross margins and minimal capex requirements, PBH converts approximately 27% of revenue to free cash flow while maintaining modest leverage at 0.59x debt/equity.
PBH acquires established OTC brands with strong consumer awareness at attractive multiples (typically 8-12x EBITDA), then drives profitability through operational improvements including SKU rationalization, marketing optimization, and supply chain efficiency. The company benefits from brand loyalty in repeat-purchase categories where consumers exhibit low price sensitivity and high switching costs. Gross margins of 55.8% reflect favorable product mix with limited manufacturing complexity (outsourced production model). Operating leverage comes from spreading fixed SG&A across acquired brands, with operating margins expanding from mid-20s to current 29.6% over the past decade. Pricing power exists in niche categories where brands hold #1 or #2 market positions.
Organic revenue growth rates in core brands (particularly Dramamine, Monistat, Clear Eyes) which signal brand health and market share trends
M&A announcements and integration execution - acquisitions typically drive 12-18 month stock rallies when accretive deals are announced at reasonable multiples
Gross margin trajectory reflecting input cost pressures (packaging, freight, raw materials) versus pricing actions and product mix shifts
Free cash flow generation and capital allocation decisions including debt paydown, share repurchases, and dividend policy
Retailer inventory destocking or restocking cycles which create quarterly volatility in shipment patterns versus consumption trends
Amazon and e-commerce channel shift reducing retail shelf space and increasing price transparency - online sales now represent 15-20% of OTC market and growing 10%+ annually, pressuring traditional retail partnerships and potentially commoditizing brands
Private label penetration in OTC categories as retailers like CVS, Walgreens, and Walmart aggressively promote store brands with 30-40% price discounts - particularly threatening in less differentiated categories
FDA regulatory changes including potential Rx-to-OTC switches that could introduce new competition or reclassification of existing products requiring additional clinical data
Large CPG conglomerates (Procter & Gamble, Johnson & Johnson, Bayer) with significantly greater marketing budgets and retail negotiating leverage competing in overlapping categories
Direct-to-consumer healthcare brands bypassing traditional retail and building customer relationships through subscription models and social media marketing, particularly threatening in women's health segment
Generic pharmaceutical manufacturers entering OTC space with lower-priced alternatives as patent cliffs create excess manufacturing capacity
Debt/EBITDA leverage of approximately 2.8-3.2x limits financial flexibility for large acquisitions and creates refinancing risk if credit markets tighten - $600M+ debt maturities concentrated in 2028-2030 period
Goodwill and intangible assets represent 65-70% of total assets ($2.2B+ on balance sheet), creating impairment risk if brand performance deteriorates or discount rates increase during valuation testing
Working capital can swing significantly based on retailer ordering patterns and promotional timing, creating quarterly cash flow volatility of $20-40M
low - OTC healthcare products exhibit defensive characteristics with consumption driven by medical need rather than discretionary spending. Categories like antifungals, motion sickness remedies, and eye care maintain stable demand through economic cycles. However, premium-priced SKUs may see modest trade-down pressure during recessions. Approximately 70% of portfolio addresses non-discretionary health needs, insulating revenue from GDP fluctuations. Historical analysis shows revenue volatility of <3% during 2008-2009 recession.
Rising rates create moderate headwinds through two channels: (1) increased interest expense on $600M+ debt load (mix of fixed and floating rate), with each 100bps rate increase adding approximately $3-4M annual interest cost on floating portion; (2) valuation multiple compression as defensive healthcare stocks trade at premium P/E ratios that contract when risk-free rates rise, making dividend yields less attractive relative to bonds. Conversely, higher rates reduce M&A activity industry-wide, potentially decreasing competitive bidding for acquisition targets.
Minimal direct credit exposure as business is primarily cash-based retail sales with limited receivables concentration. However, retailer financial health matters - bankruptcy or restructuring of major customers (representing 10-15% of revenue each for top 3 retailers) could disrupt distribution. Private label competition intensifies during credit crunches as retailers promote lower-priced alternatives, though PBH's niche categories have limited private label penetration (estimated 15-20% vs 30%+ in broader OTC market).
value/dividend - The stock appeals to value investors seeking defensive cash flow generators trading at reasonable multiples (12.4x EV/EBITDA vs 15-18x for branded pharma peers). High FCF conversion (7.6% yield) supports dividend sustainability and share repurchases. Limited growth profile (1-2% organic) means growth investors typically avoid. Hedge funds use as defensive hedge during market volatility given low beta characteristics. Long-term holders attracted to capital allocation optionality and M&A-driven value creation potential.
low - Historical beta estimated 0.6-0.7 reflecting defensive healthcare characteristics and stable cash flows. Stock exhibits lower volatility than broader market with annualized volatility typically 18-22% versus 20-25% for S&P 500. However, M&A announcements and quarterly earnings surprises can create 5-10% single-day moves. Recent 22% one-year decline likely reflects multiple compression from rising rates rather than fundamental deterioration, given stable margins and cash flow generation.
